Ultragenyx Reports Third Quarter 2020 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Ultragenyx Pharma (RARE) PT Raised to $116 at Cowen
October 28, 2020 6:59 AM EDTCowen analyst Yaron Werber raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $116.00 (from $90.00) while maintaining an Outperform rating.
The analyst commented, "RARE reported Q3:20 earnings with OpEx of $132M v our $128M estimates & steady growth in sales of Crysvita & Dojolvi.... More
Ultragenyx Pharma (RARE) Tops Q3 EPS by 14c, Revenues Beat
October 27, 2020 4:45 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.13), $0.14 better than the analyst estimate of ($1.27). Revenue for the quarter came in at $81.5 million versus the consensus estimate of $53.89 million.
Third quarter 2020 total revenue of $81.5 million and Crysvita revenue of $37.3 millionIncreased lower end of... More